10.1371/journal.pone.0187289.g004
Matilde Forcella
Matilde
Forcella
Monica Oldani
Monica
Oldani
Samantha Epistolio
Samantha
Epistolio
Stefania Freguia
Stefania
Freguia
Eugenio Monti
Eugenio
Monti
Paola Fusi
Paola
Fusi
Milo Frattini
Milo
Frattini
Evaluation of sialidase NEU3 effect on cell viability with or without gefitinib.
Public Library of Science
2017
therapies sensitivity
NSCLC cell viability
NEU 3
EGFR point mutations
TKI
Non-Small Cell Lung Cancer
Akt pathway
NEU 3 overexpressing patients
ERK pathway
lung cancer cell lines
plasma membrane-associated NEU 3 Adenocarcinoma
sialidase NEU 3
EGFR pathways activation
NEU 3 overexpression
mucosa cell line
Non-small cell lung cancer
sialidase NEU 3 overexpression
EGFR wild-type gene sequence
2017-10-31 17:47:15
Figure
https://plos.figshare.com/articles/figure/Evaluation_of_sialidase_NEU3_effect_on_cell_viability_with_or_without_gefitinib_/5557231
<p>MTT test was performed on HSAEC1, HCC4006 and H1734 cell lines transfected with either the empty vector (mock) or pcDNA3.1-HsNEU3 and then treated or not with 27 nM or 1 μM gefitinib for 36 h <i>post</i>-transfection. Data were normalized on control cells transfected with the empty vector (A). Cell viabilities of mock and NEU3 transfected cells are reported after treatment with either 27 nM (B) or 1 μM gefitinib (C). Data were normalized on control cells without drug. Values are presented as means ± standard error (SE).</p>